Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions

 

Abstract No : 9580

Abstract Type : Poster Session

Indication : NSCLC with EGFR exon 20 insertions

Intervention : TAK-788

Company : Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Technology : Small molecule

 

Results:

A total of 99 pts were included, n=28 TAK-788 and n=71 RWD; mean age 62/65 y; male 25%/46%; Asian 18%/10%; former smoker 39%/45%; brain metastases 43%/34%. In the RWD, there was no consistent regimen for second-line treatment (including 29.6% immuno-oncologic agents, 25.4% EGFR TKI, 10% docetaxel). Baseline characteristics were comparable after weighting. PFS and ORR showed statistically significant improvements with TAK-788 vs RWD (Table). Specifically, after weighting, median PFS for TAK-788 vs RWD is 7.3 vs 3.5 mo, and ORR is 43% vs 13%.

 

Conclusion:

Despite a more heavily pretreated pt population, the efficacy of TAK-788 in pts with refractory NSCLC with EGFR exon 20 insertions appears better than other second-line treatment options used in the real-world setting.

 

Commentary:

Among pretreated patients with NSCLC with EGFR exon 20 insertions, mobocertinib (TAK-788) demonstrated prolonged PFS and higher ORR compared with other second line treatment options used in real world setting

The therapeutics segment is experiencing significant NSCLC clinical trial activity, which is further expected to drive Non-Small Cell Lung Caner market growth in the coming years.

Refer to Non Small Cell Lung Cancer Market report for detailed Insights.